Trial Profile
A Retrospective Study of Risk of Cardiovascular Events in users of Antimuscarinic Drugs to treat Overactive Bladder (OAB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 May 2018
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary) ; Darifenacin; Fesoterodine; Oxybutynin; Tolterodine; Trospium chloride
- Indications Overactive bladder
- Focus Therapeutic Use
- 14 May 2018 New trial record
- 03 May 2018 Results published in the Pharmacotherapy